{"classes":[{"categories":[{"measurements":[{"comment":"No DLTs or treatment-related deaths were reported, which may be due to insufficient number of participants with events to determine MTD.","groupId":"OG000","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"'3+3' study design. MTD will be defined at the dose level of trientine prior to the level with DLT events ≧ 2/6 participants.","groups":[{"description":"trientine dihydrochloride: trientine dihydrochloride 300 - 1800MG/CAPSUE PO daily pegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1 carboplatin: carboplatin AUC 4 IV D1","id":"OG000","title":"Trientine With Chemotherapy Dose Level 1 - 6 (300 -1800mg)"}],"paramType":"NUMBER","populationDescription":"One participant receiving 600 mg/day declined the trial drugs and did not proceed with treatment.Therefore, an additional participant was included at the same dose level.","reportingStatus":"POSTED","timeFrame":"within 36 days after the start of Trientine","title":"Maximum Tolerated Dose, MTD","type":"SECONDARY","unitOfMeasure":"mg"}